Clinical Trial Detail

NCT ID NCT02287233
Title A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

acute myeloid leukemia

Therapies

Cytarabine + Venetoclax

Age Groups: senior

No variant requirements are available.